论文部分内容阅读
目的探讨核仁素(NCL)在甲状腺乳头状癌中的表达及临床意义。方法采用免疫组织化学SP染色法检测60例正常甲状腺组织与甲状腺乳头状癌中NCL、趋化因子受体-7(CCR7)与基质金属蛋白酶-9(MMP-9)的表达,分析NCL、CCR7与MMP-9的表达与性别、年龄、肿瘤大小与有无转移的关系以及核仁素与CCR7、MMP-9表达的相关性。结果 NCL在正常甲状腺及甲状腺乳头状癌中的总阳性率分别为0、100%。NCL在伴随转移组癌组织中表达于细胞核、细胞质与细胞膜;NCL在无转移组癌组织中仅表达于细胞核,差异有统计学意义(P<0.05)。不同年龄、性别、肿瘤大小的NCL表达率间的差异无统计学意义(P>0.05)。核仁素细胞核外阳性表达与CCR7与MMP-9的阳性表达呈正相关(P<0.01)。结论 NCL在甲状腺乳头状癌中表达,表达部位在转移与非转移组明显不同,且与CCR7、MMP-9表达有密切关系。核仁素可作为区别癌转移与非转移的标志。
Objective To investigate the expression of nucleolin (NCL) in papillary thyroid carcinoma and its clinical significance. Methods The expressions of NCL, CCR7 and MMP-9 in 60 normal thyroid tissues and papillary thyroid carcinoma were detected by immunohistochemical SP staining. The expressions of NCL, CCR7 And the relationship between the expression of MMP-9 and gender, age, tumor size and metastasis, as well as the correlation between nucleolin and CCR7 and MMP-9. Results The overall positive rates of NCL in normal thyroid and thyroid papillary carcinoma were 0 and 100%, respectively. NCL was expressed in the nucleus, cytoplasm and cell membrane in metastatic cancer tissues; NCL was only expressed in the nucleus in non-metastatic cancer tissues, the difference was statistically significant (P <0.05). There was no significant difference in NCL expression rates between different age, gender and tumor size (P> 0.05). The positive expression of nuclear nucleotides in nuclei was positively correlated with the positive expression of CCR7 and MMP-9 (P <0.01). Conclusion NCL is expressed in papillary thyroid carcinoma and the expression of NCL is significantly different between metastatic and non-metastatic groups, and closely related to the expression of CCR7 and MMP-9. Nucleotide can be used as a marker of cancer metastasis and non-metastasis.